|
Size: 92
Comment:
|
Size: 3172
Comment:
|
| Deletions are marked like this. | Additions are marked like this. |
| Line 2: | Line 2: |
| = Methylamino-alanine as a Potential Trigger for Neurodegenerative Disorders = By: Thita Chanthasukh, Jihun Jung, Damin Lee |
|
| Line 3: | Line 5: |
| Itt írjon a(z) Methylamino-alanine-ról/ről | Table of contents: <<TableOfContents()>> Table of contents (up to 2nd level headings only): <<TableOfContents(2)>> = heading 1st level = == heading 2nd level == === heading 3rd level === ==== heading 4th level ==== ===== heading 5th level ===== ====== no heading 6th level ====== ---- == Abstract == Scientific researches predict that by 2040, neurodegenerative diseases will overtake cancer as the second most common cause of death among elders. Neurodegenerative disorders emerge when the neurons of the nervous system lose their functions and die. In turn, it may impair cognition, mobility, sensation, and the coordination of the body. Some of the most notorious neurodegenerative diseases are Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. The effects and causes of these disorders are so diverse that even though they threaten millions of lives worldwide, many are yet to be discovered and cured. In this paper, we will be examining one potential risk factor of neurodegenerative disorders, Beta-N-methylamino-L-alanine (BMAA). Although it has been years since discovery, a large part of the potential of BMAA still remains a mystery. BMAA is a nonprotein amino acid first discovered with the high incidence of Amyotrophic Lateral Schlartosis/Parkinsonism Dementia Complex (ALS/PDC) in Guam. It is essential to understand the mechanisms and dangers of BMAA because this neurotoxin can be prevalent in all levels of the trophic level due to biomagnification. As veterinarians, we should understand the consequences of BMAA as it can be incorporated into plant and animal proteins. We will discuss the discovery, effects, and neurological disorders of BMAA. Furthermore, we will conclude the paper by assessing the significance of BMAA in our studies. == The Discovery and Structure of BMAA == == The Effect and Mechanism of BMAA == == The Effect of BMAA on Glutamate-sensitive Receptors == == The Effect of BMAA on Protein == == Latency effect of BMAA == == Potential Exposure to BMAA == == Neurodegenerative Disorders == Since the detection of BMAA in Gaum, it has been postulated that BMAA may trigger several neurodegenerative diseases: Amyotrophic Lateral Sclerosis (ALS), Parkinsonism, Alzheimer’s disease, Lewy body disease, and progressive supranuclear palsy (PSP). Generally, neurodegenerative disorders are caused by protein misfolding and aggregation, with variations in the brain where it occurs. == Conclusion == Lastly, we discussed the general information of Beta-N-methylamino-L-alanine (BMAA) and how it influences and aggregates neurodegenerative disorders. As acknowledged multiple times in the essay, extensive research is still required to cease the controversies existing regarding the presence of BMAA in certain diseases, like Alzheimer's disease. BMAA is also relevant to our studies since it serves as a great example of the trigger for glutamate receptors, which we learned about. ---- == Reference == |
Methylamino-alanine as a Potential Trigger for Neurodegenerative Disorders
By: Thita Chanthasukh, Jihun Jung, Damin Lee
Table of contents:
Contents
- Methylamino-alanine as a Potential Trigger for Neurodegenerative Disorders
- heading 1st level
Table of contents (up to 2nd level headings only):
Contents
heading 1st level
heading 2nd level
heading 3rd level
heading 4th level
heading 5th level
no heading 6th level
Abstract
Scientific researches predict that by 2040, neurodegenerative diseases will overtake cancer as the second most common cause of death among elders. Neurodegenerative disorders emerge when the neurons of the nervous system lose their functions and die. In turn, it may impair cognition, mobility, sensation, and the coordination of the body. Some of the most notorious neurodegenerative diseases are Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. The effects and causes of these disorders are so diverse that even though they threaten millions of lives worldwide, many are yet to be discovered and cured.
In this paper, we will be examining one potential risk factor of neurodegenerative disorders, Beta-N-methylamino-L-alanine (BMAA). Although it has been years since discovery, a large part of the potential of BMAA still remains a mystery. BMAA is a nonprotein amino acid first discovered with the high incidence of Amyotrophic Lateral Schlartosis/Parkinsonism Dementia Complex (ALS/PDC) in Guam. It is essential to understand the mechanisms and dangers of BMAA because this neurotoxin can be prevalent in all levels of the trophic level due to biomagnification. As veterinarians, we should understand the consequences of BMAA as it can be incorporated into plant and animal proteins. We will discuss the discovery, effects, and neurological disorders of BMAA. Furthermore, we will conclude the paper by assessing the significance of BMAA in our studies.
The Discovery and Structure of BMAA
The Effect and Mechanism of BMAA
The Effect of BMAA on Glutamate-sensitive Receptors
The Effect of BMAA on Protein
Latency effect of BMAA
Potential Exposure to BMAA
Neurodegenerative Disorders
Since the detection of BMAA in Gaum, it has been postulated that BMAA may trigger several neurodegenerative diseases: Amyotrophic Lateral Sclerosis (ALS), Parkinsonism, Alzheimer’s disease, Lewy body disease, and progressive supranuclear palsy (PSP). Generally, neurodegenerative disorders are caused by protein misfolding and aggregation, with variations in the brain where it occurs.
Conclusion
Lastly, we discussed the general information of Beta-N-methylamino-L-alanine (BMAA) and how it influences and aggregates neurodegenerative disorders. As acknowledged multiple times in the essay, extensive research is still required to cease the controversies existing regarding the presence of BMAA in certain diseases, like Alzheimer's disease. BMAA is also relevant to our studies since it serves as a great example of the trigger for glutamate receptors, which we learned about.